{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:13:49Z","timestamp":1793106829358,"version":"4.5.0"},"reference-count":46,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Chemotherapy combined with immunotherapy (CT-IO) has become the first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). Locoregional radiotherapy (LRRT) following chemotherapy has been shown to significantly improve survival outcomes in patients with dmNPC. However, it remains unclear whether LRRT provides additional benefits in the context of CT-IO. Furthermore, there is no consensus on how to identify the optimal patient population for LRRT after first-line CT-IO. <jats:bold>Methods:<\/jats:bold> This study included patients with dmNPC who received platinum-based palliative chemotherapy and anti\u2013PD-1 immunotherapy, with or without LRRT. Progression-free survival (PFS) was assessed in LRRT and non-LRRT groups using inverse probability of treatment weighting (IPTW) to mitigate selection bias. Median PFS (mPFS) at the 6-month landmark was estimated using Kaplan-Meier analyses. A novel prognostic nomogram was developed and validated to predict PFS and stratify patients by risk. Using prognostic scores from the nomogram, a model-based tree approach was employed to assess stratified treatment outcomes and identify the ideal candidates for LRRT. <jats:bold>Results:<\/jats:bold> A total of 500 patients were included, with 367 receiving LRRT and 133 not receiving it. At the 6-month conditional landmark, IPTW-adjusted Kaplan-Meier curves demonstrated significantly improved survival in the LRRT group compared with the non-LRRT group (mPFS, not reached vs 21.5 months; <jats:italic>P<\/jats:italic>&lt;.001). Patients were randomized into training and validation cohorts in a 7:3 ratio. A prognostic model integrating serum lactate dehydrogenase (LDH) level, posttreatment Epstein-Barr virus DNA level, number of metastatic lesions, and liver metastases status was developed from the training cohort and graphically represented as a nomogram. The model demonstrated favorable discrimination (C-index, 0.721; 95% CI, 0.681\u20130.761) and predictive accuracy (1-year time-dependent area under the curve [tAUC]), 0.788), and its performance was validated in the internal cohort (C-index, 0.752; 95% CI, 0.698\u20130.806; 1-year tAUC, 0.778). A tree-based risk stratification derived from the model classified patients into 2 prognostic subgroups. Low-risk patients benefited from additional LRRT (mPFS, not reached vs 23.6 months; <jats:italic>P<\/jats:italic>&lt;.001), whereas high-risk patients did not (mPFS, 18.3 vs 16.5 months; <jats:italic>P<\/jats:italic>=.210). <jats:bold>Conclusions:<\/jats:bold> In patients with dmNPC, additional LRRT following first-line CT-IO was associated with improved PFS, particularly among low-risk patients identified using a novel prognostic model.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7086","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T16:04:21Z","timestamp":1741881861000},"source":"Crossref","is-referenced-by-count":8,"title":["Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era"],"prefix":"10.6004","volume":"23","author":[{"given":"Dongxiang","family":"Wen","sequence":"first","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Luo","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongping","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longbin","family":"Xiong","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linquan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqiang","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Liang","sequence":"additional","affiliation":[{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"Department of Radiology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"},{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, Guangdong Province, China"},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL,  Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209\u2013249."},{"key":"B2","series-title":"Oral Oncol","first-page":"1007","article-title":"The strength\/weakness of the AJCC\/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement","volume":"48","author":"Lee AWM","year":"2012","unstructured":"Lee AWM, Ng WT, Chan LK,  The strength\/weakness of the AJCC\/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. Oral Oncol 2012;48:1007\u20131013."},{"key":"B3","series-title":"Cancer","first-page":"546","article-title":"Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy","volume":"122","author":"Pan JJ","year":"2016","unstructured":"Pan JJ, Ng WT, Zong JF,  Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. Cancer 2016;122:546\u2013558."},{"key":"B4","series-title":"Lancet","first-page":"64","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen YP","year":"2019","unstructured":"Chen YP, Chan ATC, Le QT,  Nasopharyngeal carcinoma. Lancet  2019;394:64\u201380."},{"key":"B5","series-title":"Nat Med","first-page":"1536","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai HQ","year":"2021","unstructured":"Mai HQ, Chen QY, Chen D,  Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med 2021;27:1536\u20131543."},{"key":"B6","series-title":"Cancer Cell","first-page":"1061","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang Y","year":"2023","unstructured":"Yang Y, Pan J, Wang H,  Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309). Cancer Cell 2023;41:1061\u20131072.e4."},{"key":"B7","series-title":"Ann Oncol","first-page":"251","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan ATC","year":"2023","unstructured":"Chan ATC, Lee VHF, Hong RL,  Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial. Ann Oncol 2023;34:251\u2013261."},{"key":"B8","series-title":"Ann Oncol","first-page":"247","article-title":"ESMO-EURACAN clinical practice guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease","volume":"34","author":"Bossi P","year":"2023","unstructured":"Bossi P, Chan AT, Even C, Machiels JP. ESMO-EURACAN clinical practice guideline update for nasopharyngeal carcinoma: adjuvant therapy and first-line treatment of recurrent\/metastatic disease. Ann Oncol 2023;34:247\u2013250."},{"key":"B9","article-title":"NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 4","author":"Pfister DG","year":"2024","unstructured":"Pfister DG, Spencer S, Adkins D,  NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 4.2024. Accessed May 1, 2024. To view the most recent version, visit https:\/\/www.nccn.org\/"},{"key":"B10","series-title":"Eur J Cancer","first-page":"117","article-title":"Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment","volume":"77","author":"Zou X","year":"2017","unstructured":"Zou X, You R, Liu H,  Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer 2017;77:117\u2013126."},{"key":"B11","series-title":"Radiother Oncol","first-page":"139","article-title":"Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy","volume":"124","author":"Rusthoven CG","year":"2017","unstructured":"Rusthoven CG, Lanning RM, Jones BL,  Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 2017;124:139\u2013146."},{"key":"B12","series-title":"PloS One","first-page":"e108070.","article-title":"Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors","volume":"9","author":"Zeng L","year":"2014","unstructured":"Zeng L, Tian YM, Huang Y,  Retrospective analysis of 234 nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis: therapeutic approaches and prognostic factors. PloS One 2014;9:e108070."},{"key":"B13","series-title":"Sci Rep","first-page":"721.","article-title":"Use of radiation therapy in metastatic nasopharyngeal cancer improves survival: a SEER analysis","volume":"7","author":"Hu J","year":"2017","unstructured":"Hu J, Kong L, Gao J,  Use of radiation therapy in metastatic nasopharyngeal cancer improves survival: a SEER analysis. Sci Rep 2017;7:721."},{"key":"B14","series-title":"Med Oncol","first-page":"224.","article-title":"Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis","volume":"32","author":"Hu SX","year":"2015","unstructured":"Hu SX, He XH, Dong M,  Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis. Med Oncol 2015;32:224."},{"key":"B15","series-title":"JAMA Oncol","first-page":"1345","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You R","year":"2020","unstructured":"You R, Liu YP, Huang PY,  Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol 2020;6:1345\u20131352."},{"key":"B16","series-title":"ESMO Open","first-page":"101629.","article-title":"Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy","volume":"8","author":"Hu YJ","year":"2023","unstructured":"Hu YJ, Lu TZ, Zhang H,  Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy. ESMO Open 2023;8:101629."},{"key":"B17","series-title":"Sci Rep","first-page":"3950.","article-title":"Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy","volume":"14","author":"Chen Y","year":"2024","unstructured":"Chen Y, Chen C, Peng H,  Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy. Sci Rep 2024;14:3950."},{"key":"B18","series-title":"Oral Oncol","first-page":"106583.","article-title":"Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma","volume":"147","author":"Liu ZQ","year":"2023","unstructured":"Liu ZQ, Zhao YN, Wu YS,  Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma. Oral Oncol 2023;147:106583."},{"key":"B19","series-title":"Oncologist","first-page":"291","article-title":"M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma","volume":"20","author":"Shen L","year":"2015","unstructured":"Shen L, Dong J, Li S,  M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma. Oncologist 2015;20:291\u2013298."},{"key":"B20","series-title":"Cancer Res Treat","first-page":"1259","article-title":"Subdivision of nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis for prediction of survival and treatment guidance","volume":"51","author":"Sun XS","year":"2019","unstructured":"Sun XS, Liang YJ, Liu SL,  Subdivision of nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis for prediction of survival and treatment guidance. Cancer Res Treat 2019;51:1259\u20131268."},{"key":"B21","series-title":"Int J Radiat Oncol Biol Phys","first-page":"581","article-title":"The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012","volume":"105","author":"Sun XS","year":"2019","unstructured":"Sun XS, Liu SL, Luo MJ,  The association between the development of radiation therapy, image technology, and chemotherapy, and the survival of patients with nasopharyngeal carcinoma: a cohort study from 1990 to 2012. Int J Radiat Oncol Biol Phys 2019;105:581\u2013590."},{"key":"B22","series-title":"Eur J Cancer","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer EA","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J,  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228\u2013247."},{"key":"B23","series-title":"Cell Rep Med","first-page":"101279.","article-title":"Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: a phase II trial","volume":"4","author":"Chen SY","year":"2023","unstructured":"Chen SY, Duan XT, Li HF,  Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: a phase II trial. Cell Rep Med 2023;4:101279."},{"key":"B24","series-title":"Int J Cancer","first-page":"2873","article-title":"Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients","volume":"145","author":"You R","year":"2019","unstructured":"You R, Liu YP, Lin M,  Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients. Int J Cancer 2019;145:2873\u20132883."},{"key":"B25","series-title":"J Am Soc Nephrol","first-page":"2916","article-title":"Effect of an increase in C-reactive protein level during a hemodialysis session on mortality","volume":"15","author":"Korevaar JC","year":"2004","unstructured":"Korevaar JC, van Manen JG, Dekker FW,  Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004;15:2916\u20132922."},{"key":"B26","series-title":"Leukemia","first-page":"2654","article-title":"A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"33","author":"Kastritis E","year":"2019","unstructured":"Kastritis E, Morel P, Duhamel A,  A revised international prognostic score system for Waldenstr\u00f6m\u2019s macroglobulinemia. Leukemia 2019;33:2654\u20132661."},{"key":"B27","series-title":"Clin Kidney J","first-page":"14","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye NC","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G,  An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J 2022;15:14\u201320."},{"key":"B28","series-title":"Int J Radiat Oncol Biol Phys","first-page":"120","article-title":"Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study","volume":"109","author":"Li WZ","year":"2021","unstructured":"Li WZ, Lv SH, Liu GY,  Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study. Int J Radiat Oncol Biol Phys 2021;109:120\u2013130."},{"key":"B29","series-title":"Int J Biostat","first-page":"45","article-title":"Model-based recursive partitioning for subgroup analyses","volume":"12","author":"Seibold H","year":"2016","unstructured":"Seibold H, Zeileis A, Hothorn T. Model-based recursive partitioning for subgroup analyses. Int J Biostat 2016;12:45\u201363."},{"key":"B30","series-title":"Head Neck Pathol","first-page":"203","article-title":"Programmed death-ligand 1 expression, microsatellite instability, Epstein-Barr virus, and human papillomavirus in nasopharyngeal carcinomas of patients from the Philippines","volume":"11","author":"Chang AMV","year":"2017","unstructured":"Chang AMV, Chiosea SI, Altman A,  Programmed death-ligand 1 expression, microsatellite instability, Epstein-Barr virus, and human papillomavirus in nasopharyngeal carcinomas of patients from the Philippines. Head Neck Pathol 2017;11:203\u2013211."},{"key":"B31","series-title":"Head Neck","first-page":"2007","article-title":"Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment","volume":"40","author":"Ono T","year":"2018","unstructured":"Ono T, Azuma K, Kawahara A,  Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment. Head Neck 2018;40:2007\u20132019."},{"key":"B32","series-title":"Int J Cancer","first-page":"2558","article-title":"Prognostic significance of tumor- infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study","volume":"142","author":"Wang YQ","year":"2018","unstructured":"Wang YQ, Chen YP, Zhang Y,  Prognostic significance of tumor- infiltrating lymphocytes in nondisseminated nasopharyngeal carcinoma: a large-scale cohort study. Int J Cancer 2018;142:2558\u20132566."},{"key":"B33","series-title":"Transl Lung Cancer Res","first-page":"1636","article-title":"Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail","volume":"12","author":"Cali Daylan AE","year":"2023","unstructured":"Cali Daylan AE, Halmos B. Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail. Transl Lung Cancer Res 2023;12:1636\u20131642."},{"key":"B34","series-title":"J Immunother Cancer","first-page":"e004389","article-title":"Personalized neoantigen vaccine combined with PD-1 blockade increases CD8 (+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models","volume":"10","author":"Chen H","year":"2022","unstructured":"Chen H, Li Z, Qiu L,  Personalized neoantigen vaccine combined with PD-1 blockade increases CD8 (+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models. J Immunother Cancer 2022;10:e004389."},{"key":"B35","series-title":"Cell Rep Methods","first-page":"100596.","article-title":"Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy","volume":"3","author":"Zhao J","year":"2023","unstructured":"Zhao J, Dong Y, Bai H,  Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy. Cell Rep Methods 2023;3:100596."},{"key":"B36","series-title":"Signal Transduct Target Ther","first-page":"258.","article-title":"Radiotherapy combined with immunotherapy: the dawn of cancer treatment","volume":"7","author":"Zhang Z","year":"2022","unstructured":"Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258."},{"key":"B37","series-title":"Nat Rev Cancer","first-page":"313","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa W","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD,  Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 2018;18:313\u2013322."},{"key":"B38","series-title":"Cell Death Dis","first-page":"1013.","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova J","year":"2020","unstructured":"Fucikova J, Kepp O, Kasikova L,  Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 2020;11:1013."},{"key":"B39","series-title":"Cell Death Dis","first-page":"679.","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu S","year":"2023","unstructured":"Liu S, Wang W, Hu S,  Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity. Cell Death Dis 2023;14:679."},{"key":"B40","series-title":"Clin Cancer Res","first-page":"1709","article-title":"The reciprocity between radiotherapy and cancer immunotherapy","volume":"25","author":"Wang Y","year":"2019","unstructured":"Wang Y, Liu ZG, Yuan H,  The reciprocity between radiotherapy and cancer immunotherapy. Clin Cancer Res 2019;25:1709\u20131717."},{"key":"B41","series-title":"Oral Oncol","first-page":"105736.","article-title":"Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma","volume":"126","author":"Chan SK","year":"2022","unstructured":"Chan SK, Lin C, Huang SH,  Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma. Oral Oncol 2022;126:105736."},{"key":"B42","series-title":"Oral Oncol","first-page":"73","article-title":"Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma","volume":"94","author":"Sun XS","year":"2019","unstructured":"Sun XS, Liang YJ, Liu SL,  Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma. Oral Oncol 2019;94:73\u201379."},{"key":"B43","series-title":"J Clin Oncol","first-page":"JCO2018777847.","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","volume":"36","author":"Chan ATC","year":"2018","unstructured":"Chan ATC, Hui EP, Ngan RKC,  Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 2018;36:JCO2018777847."},{"key":"B44","series-title":"Clin Cancer Res","first-page":"1016","article-title":"Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic\/recurrent nasopharyngeal carcinoma","volume":"16","author":"Wang WY","year":"2010","unstructured":"Wang WY, Twu CW, Chen HH,  Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic\/recurrent nasopharyngeal carcinoma. Clin Cancer Res 2010;16:1016\u20131024."},{"key":"B45","series-title":"J Clin Oncol","first-page":"704","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang FH","year":"2021","unstructured":"Wang FH, Wei XL, Feng J,  Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol 2021;39:704\u2013712."},{"key":"B46","series-title":"Lancet Oncol","first-page":"1162","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang Y","year":"2021","unstructured":"Yang Y, Qu S, Li J,  Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021;22:1162\u20131174."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/4\/article-e247086.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/4\/article-e247086.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/4\/article-e247086.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:46:14Z","timestamp":1744202774000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/4\/article-e247086.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":46,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7086","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}